We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.
|03 Nov 2023|
|24 Oct 2023|
|23 Oct 2023|
|06 Sep 2023|
|25 Jul 2023|
Swiss EQ Technology & Innovation Days
|November 14-16, 2023|
Full-Year 2023 Financial Results reporting*
|February 6, 2024|
Annual General Meeting of Shareholders
|April 11, 2024|
First Quarter 2024 Financial Results reporting*
|April 25, 2024|
Half-Year 2024 Financial Results reporting*
|July 25, 2024|
*We will be in a silent period for 10 days ahead of the financial reporting.
The company reports on its financial performance on a quarterly basis starting its financial year on January 01. Read all the latest financial information from Idorsia, including our financial guidance and how the company is funded.
Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.
Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.
The company publishes a Half Year and Annual Report report summarizing its operational and financial performance, starting its financial year on January 01.
The registered shares of Idorsia Ltd were listed on the SIX Swiss Exchange on June 16, 2017 (symbol: IDIA). Get all the latest information about our stock, interact with charting tools, and see what the covering analysts think about the company's future performance.